Ep 61: Elias Arnér, redox & EbsArgent. Ceftazidime-avibactam for P. aeruginosa treatment. FusB-mediated resistance.
In this episode, we bring you an interview with Professor Elias Arnér from the Karolinska Institute. After a long international career in redox biology, Professor Arnér became CEO of Thioredoxin Systems, the company behind a potential new antibiotic with a novel target and mode of action: EbsArgent. We explore his background, the lessons he has learned, and what makes this new drug candidate so unique.
In the news section, Elin brings us a recent article on the resistance and potential collateral sensitivity of Ceftazidime-avibactam to treat P. aeruginosa strains. Eva shares the latest publication at our center, with PhD student Adrián González López’s work on the mechanisms behind FusB-mediated resistance in Staphylococcus aureus.
We hope you enjoy this month’s episode, and see you on the next one!
You can follow us and subscribe to our podcast to get new episodes directly in your preferred device and platform:
Relevant links:
- Prof. Elias Arnér website at the Karolinska Institute.
- Thioredoxin Systems's website.
Further Reading:
- Synergistic antibacterial effect of silver and ebselen against multidrug-resistant Gram-negative bacterial infections. Original publication on the mechanism of action of EbsArgent.
- Additional publications mentioned in the interview showing efficacy of EbsArgent against UTI in mouse models:
- Ceftazidime-avibactam use selects multidrug-resistance and prevents designing collateral sensitivity-based therapies against Pseudomonas aeruginosa. First article covered in the news.
- Structural mechanism of FusB-mediated rescue from fusidic acid inhibition of protein synthesis. Second article covered in the news.
If you have any comments and suggestions you can email us here, or tweet to us (@UAC_UU) using the hashtag #theAMRStudio.